Market Place
Sourcing Support
Protagonist Reports Durable Hematocrit Control in REVIVE Study
09 Dec 2024 //
ACCESSWIRE
Protagonist Therapeutics to Join Evercore ISI HealthCONx 2024 Conf
22 Nov 2024 //
ACCESSWIRE
Protagonist`s PN-881 as IL-17 Antagonist Development Candidate
21 Nov 2024 //
ACCESSWIRE
Protagonist to Announce IL-17 Antagonist Development Candidate
19 Nov 2024 //
ACCESSWIRE
Protagonist Announces Positive Results from Iconic Psoriasis Study
18 Nov 2024 //
ACCESSWIRE
Protagonist Reports Q3 2024 Results & Update
07 Nov 2024 //
ACCESSWIRE
Protagonist to Present Final REVIVE Phase 2 Data at ASH 2024
05 Nov 2024 //
ACCESSWIRE
Protagonist Reports Q2 2024 Results And Provides Corporate Update
06 Aug 2024 //
ACCESSWIRE
Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress
14 Jun 2024 //
ACCESSWIRE
Protagonist At Jefferies Healthcare Conference 2024
31 May 2024 //
ACCESSWIRE
Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024
14 May 2024 //
ACCESSWIRE
Protagonist Q1 2024 Results, Corporate Update
07 May 2024 //
ACCESSWIRE
Protagonist At Citizens, CapOne Biotech Conferences
07 May 2024 //
ACCESSWIRE
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment
26 Mar 2024 //
ACCESSWIRE
Protagonist Announces Closing of Worldwide Rusfertide License
18 Mar 2024 //
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
06 Mar 2024 //
ACCESSWIRE
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
ACCESSWIRE
New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide
21 Feb 2024 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
20 Feb 2024 //
ACCESSWIRE
Takeda wagers $300M on Protagonist’s PhIII rare disease drug
01 Feb 2024 //
ENDPTS
Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide
31 Jan 2024 //
ACCESSWIRE
Protagonist to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
29 Jan 2024 //
PRESS RELEASE
Protagonist Therapeutics to Participate in 42nd Annual J.P. Morgan Conference
03 Jan 2024 //
ACCESSWIRE
Protagonist Earns $10 Million Payment for Phase 2bof JNJ-2113
13 Dec 2023 //
ACCESSWIRE
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at ASH
12 Dec 2023 //
ACCESSWIRE
Protagonist Announces Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113
27 Nov 2023 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
16 Nov 2023 //
ACCESSWIRE
Protagonist Ranked in Top 3% of Fastest-Growing Companies in North America
09 Nov 2023 //
ACCESSWIRE
Protagonist Announces Abstracts Selected for Oral and Poster Presentations
02 Nov 2023 //
ACCESSWIRE
Protagonist Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
01 Nov 2023 //
ACCESSWIRE
Protagonist Announces Achievement of $50M Milestone Event
01 Nov 2023 //
ACCESSWIRE
Protagonist Announces Appointment of Daniel Swisher to Its Board of Directors
30 Oct 2023 //
ACCESSWIRE
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
09 Oct 2023 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
03 Oct 2023 //
ACCESSWIRE
Protagonist Therapeutics to Present at Upcoming Investor Conferences
05 Sep 2023 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
16 Aug 2023 //
ACCESSWIRE
Protagonist Receives $34 Million from Warrant Exercises
09 Aug 2023 //
ACCESSWIRE
Protagonist Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
18 Jul 2023 //
ACCESSWIRE
J&J psoriasis drug licensed from Protagonist doesn`t top competition
03 Jul 2023 //
ENDPTS
Durability of Response of Rusfertide in Polycythemia Vera Featured at EHA
09 Jun 2023 //
ACCESSWIRE
Protagonist Announces Acceptance of Abstract for Oral Presentation at EHA
06 Jun 2023 //
ACCESSWIRE
Protagonist to Participate in the 2023 Jefferies Healthcare Conference
01 Jun 2023 //
ACCESSWIRE
Protagonist Reports Positive Results from Ph1 &Preclinical Studies Oral JNJ-2113
12 May 2023 //
PR NEWSWIRE
Protagonist Therapeutics Announces Presentations at the 2023
11 May 2023 //
PR NEWSWIRE
Protagonist Therapeutics to Participate in the JMP Securities Life Conference
11 May 2023 //
PR NEWSWIRE
Protagonist Reports 1Q FYR 2023 and Provides Corporate Update
04 May 2023 //
PR NEWSWIRE
Protagonist Announces Pricing of $100 Million Public Offering of Shares
04 Apr 2023 //
ACCESSWIRE
Protagonist Announces Results from REVIVE Study of Rusfertide
15 Mar 2023 //
ACCESSWIRE
Protagonist Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
ACCESSWIRE
Protagonist`s story turns for the better on psoriasis data
08 Mar 2023 //
FIERCE BIOTECH
Protagonist Announces Positive Results for Ph2b FRONTIER 1 Trial of Oral IL-23
07 Mar 2023 //
PR NEWSWIRE
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan
21 Dec 2022 //
PRNEWSWIRE
Protagonist to Participate in the JMP Securities Hematology and Oncology Summit
01 Dec 2022 //
PRNEWSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
16 Nov 2022 //
PRNEWSWIRE
Drugs up for sale, on the shelf in biotech pipeline clear-outs
09 Nov 2022 //
FIERCEBIOTECH
Protagonist Therapeutics Announces Presentations at the ASH 2022 Meeting
03 Nov 2022 //
PRNEWSWIRE
